Article
Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion.
American journal of hematology - 1 Aug 2023
Daver Naval G, Iqbal Shahed, Huang Julie, Renard Camille, Lin Joyce, Pan Yang, Williamson Mellissa, Ramsingh Giridharan
Abstract excerpt
Approximately 5% to 15% of acute myeloid leukemia (AML) patients have TP53 gene mutations (TP53m), which are associated with very poor outcomes. Adults (≥18 years) with a new AML diagnosis were included from a nationwide, de-identified, real-world database. Patients receiving first-line therapy were divided into three cohorts: venetoclax (VEN) + hypomethylating agents (HMAs; Cohort A), intensive chemotherapy...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.